Silence Therapeutics announced highly positive topline results from its Phase 2 SANRECO trial for divesiran, a treatment for polycythemia vera, exceeding expectations. The drug met both primary and key secondary endpoints with strong efficacy and a favorable safety profile, leading to a significant surge in the company's stock price.
Silence Therapeutics reported 'best-case outcome' results from its Phase 2 SANRECO trial for divesiran, a treatment for polycythemia vera. The drug demonstrated strong efficacy, with 88% of treated patients achieving the primary endpoint compared to 19% for placebo, and a favorable safety profile. This is a major positive catalyst for the company, significantly de-risking the drug's development and paving the way for a Phase 3 trial in early 2027. The market reacted strongly, with SLN stock surging, indicating increased investor confidence in the drug's commercial potential and the company's future prospects. This news has immediate positive implications for SLN shareholders and positions the company as a leader in the polycythemia vera treatment space.